Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2010 Results
Date:11/3/2010

s for tasimelteon in N24HSWD.   General and administrative (G&A) expenses were $2.1 million for the third quarter of 2010, compared to $2.8 million for the second quarter of 2010 and $5.3 million for the third quarter of 2009.  The decrease in G&A expenses in the third quarter of 2010 relative to the second quarter of 2010 is primarily due to lower non-cash stock-based compensation costs in the third quarter of 2010. Employee stock-based compensation expense recorded in the third quarter of 2010 totaled $0.8 million, compared to $1.6 million for the second quarter of 2010 and $3.3 million for the third quarter of 2009.  The decrease in employee stock-based compensation expense in the third quarter of 2010 relative to the second quarter of 2010 is the result of the cancellation of unvested options in the third quarter of 2010, which reduced the third quarter 2010 expense. -Tax provision: Vanda recorded a tax benefit of $2.3 million in the third quarter of 2010. The tax provision is based on a projected effective tax rate for 2010 applied to the year-to-date pre-tax book income with the addition or subtraction of discrete items.  The quarterly tax provision is not indicative of estimated quarterly cash tax payments. The tax provision rate applied in 2010 was determined primarily based upon a net increase in valuation allowance for excess of the deferred revenue recorded from the $200.0 million upfront milestone payment received from Novartis at the end of 2009 over the existing tax attributes utilized. The provision also includes the impact of tax credits relating to the orphan drug designation for tasimelteon. Vanda will continue to evaluate its qualified expenses for the orphan drug tax credit and, to the extent that actual qualified expenses vary significantly from Vanda's estimates, Vanda's effective tax rate will increase or decrease accordingly.  -

Our private letter ruling request to the Internal Revenue Service fr
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pa. , Sept. 18, 2014  Iliad Neurosciences, ... approaches to diagnosing and treating Autism Spectrum Disorders (ASD) ... License Agreement with The Research Foundation for The State ... Iliad will provide a new biomarker to identify an ... susceptibility to ASD. This biomarker is expected to be ...
(Date:9/18/2014)... 18, 2014  Decision Resources Group finds that Regeneron,s ... (VEGF) agent for wet AMD, is equally likely to ... Genentech,s Lucentis, which is the standard of care for ... (MCO) directors do not identify a clear clinical or ... than Lucentis to be listed on tier 1 or ...
(Date:9/18/2014)... MARIETTA, Ga. , Sept. 18, 2014 /PRNewswire/ ... ), an integrated developer, processor and marketer of ... human amniotic membrane, announced today that it has ...  Through the agreement, MiMedx will provide its dehydrated ... to be marketed non- exclusively on a private ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3
... 30 A partnership announced today between Medical City Hospital ... of potential life-saving technology, as Medical City recently helped outfit all ... devices. , , ... The LIFENET device, a unique combination of web, broadband and medical ...
... LONDON , NEW YORK and HAMILTON, Bermuda , ... private equity firm focused on the biotechnology and pharmaceutical industries, announced today ... TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also ... , , ...
Cached Medicine Technology:Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 2Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 3Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 4Medical City Hospital Partners With Dallas Fire-Rescue to Outfit First Mobile Units in Dallas County With Advanced EKG Technology 5Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 2Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 3Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis 4
(Date:9/19/2014)... Indiana Fiber Network, LLC (IFN), the ... of its Fiber Transport Services, adding Point of Presence ... establishing a PoP at Cermak, IFN enables interconnect opportunities ... high bandwidth fiber transport service to US and Global ... President of Sales and Marketing August Zehner, establishing a ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered with ... Coach Christi Hall to campus. , Hall’s journey to a ... gaining weight as a result of years of medication. Through ... nutrition. One year later she had lost 50 pounds, lowered ... and cardio. , After joining the YMCA staff, she furthered ...
(Date:9/19/2014)... Newport News, Va. (PRWEB) September 19, 2014 ... at Warwick Forest, a skilled nursing center that offers rehabilitation ... But they will this weekend when a young couple marries ... together and with their combined 140 years of marriage have ... , Sarah Horky, 18, and Dan Eads, 20, may ...
(Date:9/18/2014)... 19, 2014 Today, Zane Benefits, the ... why to switch employees to individual health insurance. ... be more familiar with traditional, group health insurance, there ... employees happier. , The new article provides the ... health insurance rather than group health insurance, and why ...
(Date:9/18/2014)... OR (PRWEB) September 18, 2014 Active ... 50 and older as fully participating members of society ... lifestyle. To celebrate, The Stafford – a boutique retirement ... 97034 – will host two screenings of Cyber-Seniors - ... excited for our residents to watch this great film,” ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 2Health News:Young Couple Inspired by Residents Of The Gardens At Warwick Forest To Wed There Saturday 3Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2
... leaders in diagnosing and treating Lyme disease, has launched a new website ... treatment and cure of this highly debated disease. , ... Havertown, PA ... launched a new web site today that is dedicated to giving advanced, ...
... been named president of RetireSafe, a national bipartisan, non-profit ... the options and benefits of retired and retiring Americans ... He has served as a member of the ... providing leadership in multiple areas that engage all facets ...
... patient-centered CERWASHINGTON, May 19 Joining ... the New Democrat Coalition, Tony Coelho, chairman of ... with reporters and announced PIPC,s support for the ... an important step forward for patients and caregivers, ...
... small study , , TUESDAY, May 19 (HealthDay News) -- ... restored blood flow to hearts with blocked arteries for ... reported. , "I think this is very good news ... line and have no options left," said Dr. Douwe ...
... /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of ... its primary supplier, Atomic Energy of Canada Limited ... medical isotopes, primarily molybdenum-99 (Mo-99) used in the ... MDS Nordion that they anticipate the National Research ...
... First, New York State nonprofit outpatient clinics ... Medicaid, Medicaid managed care, Medicare, and insurance billing ... healthiest organization. Millin Associates ( www.millinmedical.com ... for 27 years, provides expanded services and next-generation ...
Cached Medicine News:Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 2Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 3Health News:RetireSafe Names Thair Phillips as President 2Health News:PIPC Supports New Comparative Effectiveness Research (CER) Bill 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 2Health News:Stem Cells May Offer New Way to Treat Blocked Arteries 3Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 2Health News:MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption 3Health News:Nonprofit Outpatient Clinics and Social Service Agencies Outsource Billing to Increase Profits 2
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... 2 fume containment system ... benchtop equipment. Even large ... inside the Hyperclean 2. ... system unit comes complete with ...
Medicine Products: